25 active not recruiting, 13 completed, 12 recruiting, 11 terminated. 27 Phase 2, 21 Phase 1, 16 Not applicable, 8 Phase 3, 2 Early Phase 1.
Follow Stage IIIA Lung Cancer AJCC v8: new trials by email Literature Review of Stage IIIA Lung Cancer AJCC v8 trials Research Report on Stage IIIA Lung Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Fianlimab - Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-05-02 | 2026-10-01 |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Biospecimen Collection, Computed Tomography, Durvalumab - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 306 | 2025-04-01 | 2026-10-19 |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer Surgical Procedure, Cisplatin, Carboplatin - Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 37 | 2024-12-11 | 2026-09-02 |
| Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung Best Practice, Nicotine Replacement, Quality-of-Life Assessment - Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma | Not applicable | Withdrawn | Ohio State University Comprehensive Cancer Center | 2024-01-01 | 2024-04-12 | |
| Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Lung Carcinoma, Lung Non-Small Cell Carcinoma | Not applicable | Recruiting | Northwestern University | 70 | 2023-11-20 | 2026-05-29 |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer EMB-01, Osimertinib - Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Shanghai EpimAb Biotherapeutics Co., Ltd. | 115 | 2023-06-01 | 2023-06-01 |
| Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | University of Southern California | 5 | 2022-12-07 | 2026-01-29 |
| Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue Exercise Counseling, Exercise Intervention, Internet-Based Intervention - Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Not applicable | Terminated | Mayo Clinic | 7 | 2022-08-17 | 2025-02-07 |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | University of California, Irvine | 6 | 2022-07-20 | 2026-10-06 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial Best Practice, Exercise Intervention, Physical Therapy - Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 100 | 2022-04-14 | 2025-11-21 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Cobalamin, Dexamethasone, Docetaxel - Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | SWOG Cancer Research Network | 82 | 2022-03-15 | 2026-05-18 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Biopsy, Osimertinib, Triptolide Analog - Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2022-03-07 | 2026-03-05 |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer Aurora A Kinase Inhibitor LY3295668, Osimertinib - Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2022-02-17 | 2026-09-18 |
| ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy Cisplatin, Durvalumab, Etoposide - Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 1 | 2021-12-10 | 2023-06-13 |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel - Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-12-06 | 2026-06-30 |
| A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence Quality-of-Life Assessment, Questionnaire Administration, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine - Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma | Early Phase 1 | Completed | Roswell Park Cancer Institute | 20 | 2021-11-22 | 2026-03-17 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer Atezolizumab, Biopsy, Biospecimen Collection - Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8 | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2021-09-09 | 2023-09-26 |
Showing 20 of 67. Sign in to see all of them.
Lung Neoplasms (67) · Carcinoma, Non-Small-Cell Lung (39) · Colorectal Neoplasms (5) · Melanoma (4) · Neoplasm Metastasis (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Renal Cell (3) · Ovarian Neoplasms (3) · Small Cell Lung Carcinoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Liver Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Ureteral Neoplasms (2) · Urinary Bladder Neoplasms (2)
Lung Diseases (67) · Neoplasms by Site (67) · Respiratory Tract Diseases (67) · Respiratory Tract Neoplasms (67) · Thoracic Neoplasms (67) · Neoplasms (66) · Bronchial Neoplasms (41) · Carcinoma, Bronchogenic (41) · Neoplasms by Histologic Type (11) · Digestive System Diseases (9) · Carcinoma (8) · Digestive System Neoplasms (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Neoplasms, Glandular and Epithelial (8)
Immunoglobulin G (14) · Disulfides (13) · Pemetrexed (12) · pembrolizumab (11) · Specimen Handling (10) · Carboplatin (9) · Nivolumab (9) · durvalumab (9) · Cisplatin (8) · Magnetic Resonance Spectroscopy (8) · 1,2-diaminocyclohexaneplatinum II citrate (7) · Paclitaxel (7) · Platinum (7) · Taxes (7) · Radiation (6)
M.D. Anderson Cancer Center (21) · City of Hope Medical Center (7) · National Cancer Institute (NCI) (7) · Mayo Clinic (5) · Ohio State University Comprehensive Cancer Center (5) · Roswell Park Cancer Institute (5) · Jonsson Comprehensive Cancer Center (2) · SWOG Cancer Research Network (2) · University of California, San Francisco (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Rahul Aggarwal (1) · Rutgers, The State University of New Jersey (1)
United States (65) · Guam (3) · Puerto Rico (2) · Chile (1) · China (1) · Colombia (1) · Mexico (1)
Kathrin Milbury (2) · Xiuning Le (2) · Anne Reb (1) · Anne Reb, NP, PhD (1) · Anne S Tsao (1) · Anurag K Singh (1) · Arya Amini (1) · Aung Naing, MD (1) · Betty Ferrell (1) · Carl M Gay, MD,PHD (1) · Carlos E. Vargas, M.D. (1) · Carolyn J Presley, MD (1) · Carolyn J Presley, MD, MHS (1) · Carolyn Presley, MD (1) · Daniel Morgensztern, MD (1)
PMID 41747891, PMID 42335416, PMID 33415649, PMID 33878954, PMID 33909232, PMID 34036820, PMID 34562230, PMID 34663123, PMID 34965890, PMID 35297944, PMID 35537412, PMID 36040670, PMID 37129197, PMID 37328287, PMID 38197040, PMID 38351528, PMID 38572955, PMID 39816915, PMID 39886125, PMID 39903538, PMID 39945382, PMID 40580957, PMID 41911908, PMID 42830627
P30CA033572 (5), U10CA180888 (3), P30CA060553 (2), U10CA180820 (2), U10CA180821 (2), K07CA215546 (1), K76AG074923 (1), P30CA014089 (1), P30CA016672 (1), P30CA072720 (1), P30CA093373 (1), P30CA138292 (1), P50CA217691 (1), R01CA155196 (1), R01CA222382 (1)